Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says

Executive Summary

Decrease is part of a trend of increasing non-personnel expenses related to human drug review, which may indicate FDA cost containment, but also comes with another user fee increase.


Related Content

Thanks Sequester: FDA’s Human Drug Review Costs Decrease To Pre-FY 2011 Level
Obama’s FY 2015 Budget Is A Non-Starter, But Is It Still Bad For FDA?
PDUFA, Biosimilar Application Fees To Rise 10.7%; FDA’s Workload Adjuster Needs Work
Encore? FDA Could Come Close To Record 2012 NME Count This Year
PhRMA, BIO’s PDUFA V Application Tracker Could Inform “Course Corrections”
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?
PDUFA Communications Hurt By Sequestration As Late-Stage Meetings Begin
Should FDA Be Forced To Consider Development Time And Cost?
FDA Drug Review Costs Rise, But Personnel Spending Flattens
FDA Spending Less Time On INDs, More On NDAs and BLAs





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts